Key Product Details

Species Reactivity

Mouse

Applications

Flow Cytometry

Label

PE/Cy7 (Excitation = 488 nm, Emission = 778 nm)

Antibody Source

Monoclonal Rat IgG2A Clone # 29A1.4

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all NKp46/NCR1 Antibodies »

Product Specifications

Immunogen

Murine myeloma cell line NSO-derived recombinant mouse NKp46-Fc chimera
Glu22-Asn255
Accession # Q8C567

Specificity

Detects mouse NKp46/NCR1 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) NKp30, rhNKp44, rhNKp46, or rhNKp80 is observed.

Clonality

Monoclonal

Host

Rat

Isotype

IgG2A

Applications for NKp46/NCR1 Antibody (29A1.4) [PE/Cy7]

Application
Recommended Usage

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined. For optimal results using our Tandem dyes, please avoid prolonged exposure to light or extreme temperature fluctuations. These can lead to irreversible degradation or decoupling. When staining intracellular targets, specific attention to the fixation and permeabilization steps in your flow protocol may be required. Please contact our technical support team at technical@novusbio.com if you have any questions.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Formulation

PBS

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark. Do not freeze.

Background: NKp46/NCR1

NKp46 (also known as natural cytotoxicity receptor 1, NCR1), is a ~46 kDa Type 1 transmembrane protein and a member of the immunoglobulin superfamily (1). NKp46 is highly conserved in mammals and can be characterized by two extracellular C2-type Ig-like domains followed by a stalk region (1). NKp46 is expressed by activated and resting natural killer (NK) cells, innate lymphoid cell (ILC) 1, and a small population of T lymphocytes (1). NKp46, along with NKp30 and NKp44, are activating receptors that have been collectively termed the natural cytotoxicity receptors (NCRs) (2). The NKp46 and NKp30 receptors play a major role in triggering some of the key lytic activities of NK cells (2). NKp46 is the only cytotoxicity receptor with a mouse orthologue, known as mNKp46 (2).

NKp46 plays a critical role in the NK-cell lysis of allogenic, autologous, and xenogeneic cells (3). Activation of NKp46 signaling is mediated via its association with immunoreceptor tyrosine-based activation motif (ITAM) bearing molecules CD3zeta and FcRgamma (3). Upon receptor-engagement NK-cell cytotoxic activity and cytokine release occurs (3). This NKp46 signaling can be blocked with anti-NKp46 monoclonal antibody mediated cross-linking which causes calcium release and interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) secretion (3). NKp46 recognizes multiple ligands presented on tumor cells or pathogens and infected cells including influenza virus hemagglutinin and the parainfluenza virus hemagglutinin neuraminidase (2). Additional ligands for the NKp46 receptor include heparan sulfate (HS) glycosaminoglycans (GAGs), hemagglutinin of human vaccina virus, and vimentin expressed on cells infected with Mycobacterium tuberculosis (3).

NKp46 and its NCR counterparts have shown to be successful targets for cancer immunotherapy. More specifically, human and mouse NKp46 has shown promise in virotherapy due to its ability to stimulate NK cell activation by binding to reovirus sigma1 protein in a sialic acid-dependent manner (3). Another approach for NKp46 in cancer immunotherapy is through the use of NCR based chimeric antigen receptors (CARs). In this therapy, NCR1 supplied human T cells with anti-tumor properties via cytokine secretion, upregulation of activation markers, improved expansion, and cytotoxicity in both mouse and in vitro models (3).

References

1. Barrow, A. D., Martin, C. J., & Colonna, M. (2019). The Natural Cytotoxicity Receptors in Health and Disease. Frontiers in immunology, 10, 909. https://doi.org/10.3389/fimmu.2019.00909

2. Mandelboim, O., & Porgador, A. (2001). NKp46. The international journal of biochemistry & cell biology, 33(12), 1147-1150. https://doi.org/10.1016/S1357-2725(01)00078-4

3. Barrow, A. D., Martin, C. J., & Colonna, M. (2019). The Natural Cytotoxicity Receptors in Health and Disease. Frontiers in immunology, 10, 909. https://doi.org/10.3389/fimmu.2019.00909

Alternate Names

CD335, Ly94, MAR-1, NCR1

Gene Symbol

NCR1

Additional NKp46/NCR1 Products

Product Documents for NKp46/NCR1 Antibody (29A1.4) [PE/Cy7]

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for NKp46/NCR1 Antibody (29A1.4) [PE/Cy7]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.